Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Connecticut for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Connecticut only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Connecticut (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Erol Verter (NPI 1548610454)

Field	Value
Entity Type	Individual
Organization	Erol Verter
Address	148 East Ave Ste 3k
City	Norwalk
State	CT
ZIP	06851
Taxonomy	Ophthalmology Physician
NPI Enumerated	June 21, 2016

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused ophthalmology practice with total Medicare revenue of $1.7M and no Medicaid billing on file; the absence of Medicaid activity makes the provider functionally single-payer (Medicare) in the claims data available. The NPI has been enumerated since 2016-06-21 (~10 years ago), indicating about a decade of billing history to evaluate.

Revenue is highly concentrated in a small set of drug and injection codes: the precomputed top 3 Medicare codes account for 72.0% of this provider's total Medicare revenue, and J0178 alone represents $933K revenue (54.2% of this provider's total Medicare revenue). That concentration implies the business is materially dependent on a narrow set of high-cost intravitreal drug administrations for its revenue stream.

The service mix is consistent with a retina-focused ophthalmology practice. Top codes are injection and intravitreal drug administrations (J0178, J2777) and a standalone intravitreal injection procedure (67028), alongside retinal imaging (92134) and multiple specific biologic drugs (Q5128, J2781), which together point to routine management of retinal disease with frequent in-office injections and diagnostic imaging.

Clinical operations appear to lean heavily on retinal imaging and diagnostics as a complement to injections: 92134 produced 1.7K claims and $57.5K revenue (3.3% of Medicare revenue) and ranks in the 95th percentile nationally, described as "notably above typical national volume". This elevated imaging volume relative to peers supports the conclusion that the practice performs high-throughput retinal evaluation and follow-up tied to injection care pathways.

Competitive standing for the primary drug J0178 is solid but not dominant: J0178 ranks #931 of 3204 providers nationally (71th percentile; typical, unremarkable volume for this code), indicating meaningful but not exceptional share of aflibercept administration compared with national peers. Other injected drugs show modest to low national standing (for example J2777 ranks #1307 of 2039 providers nationally (36th percentile; typical, unremarkable volume)), so the provider is a credible but not leading national deliverer of these agents.

Encounter-level E/M activity shows above-typical new patient visits alongside routine established-patient care: 99204 is in the 94th percentile and described as "notably above typical national volume" (134 claims, $16.9K revenue, 1.0% of Medicare revenue), while established-visit codes such as 92014 and 99214 are present at typical-to-above-typical volumes (92014 ranks in the 83th percentile). This pattern suggests the practice receives a steady inflow of new referrals or complex new evaluations in addition to recurring follow-up for established retinal patients.

There is an operational finance implication from high per-claim drug payments and use of unclassified drug billing: J3490 appears with 43 claims at $2269 avg paid/claim and $97.6K revenue (5.7% of Medicare revenue). While J3490 ranks in the 35th percentile nationally (typical, unremarkable volume), the elevated average paid per claim indicates occasional use of high-cost or pass-through medications billed under unclassified drug codes that merit reconciliation for procurement and reimbursement alignment.

Overall, this NPI presents as a decade-old, Medicare-centered retinal injection practice with concentrated revenue reliance on intravitreal drug administrations (top 3 codes = 72.0% of Medicare revenue), above-typical diagnostic imaging throughput (92134 notably above typical), and a meaningful flow of new patient evaluations; competitively the provider is a solid regional participant for anti-VEGF and related retinal services but not an outlier leader on national drug-administration rankings.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

20 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	1,360	$690	$933K
J2777	Injection, faricimab‑svoa, 0.1 mg	6,780	$30	$196.6K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	1,020	$110	$108.1K
J3490	Unclassified drugs	40	$2,270	$97.6K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	330	$220	$70.4K
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	510	$120	$61.2K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	1,740	$30	$57.5K
J2778	Injection, ranibizumab, 0.1 mg	280	$180	$51K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	450	$100	$45.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	380	$100	$38.8K

Showing 1–10 of 20

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Connecticut Distribution

Erol Verter — 2 of 20 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Connecticut

Full comparison — all codes billed, vs. state median

20 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	13	40	830	$690	$713.1K
J2777	19	30	8,190	$30	$340.4K
J2778	12	20	410	$180	$117.8K
Q5128	2	10	300	$220	$105.2K
J3490	12	20	50	$1,380	$76K
67028	14	50	540	$100	$66.4K
J2781	4	10	440	$120	$55.7K
92014	78	580	100	$90	$18.6K
67036	8	10	20	$970	$18.4K
92012	172	300	120	$70	$15.2K

Showing 1–10 of 20

Related Providers

Other providers that share a Tax Identification Number (TIN) with Erol Verter, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Refocus Eye Health Of Central Connecticut, P.C.	CT	Ophthalmology Physician	$0	$8.2M
David Tom	CT	Ophthalmology Physician	$2.5M	$0
John Huang	CT	Ophthalmology Physician	$2M	$0
Jerry Tsong	CT	Ophthalmology Physician	$1.9M	$0
Gregory Haffner	CT	Ophthalmology Physician	$1.4M	$0
Neil Kalbag	CT	Ophthalmology Physician	$1.1M	$0
Patrick Coady	NJ	Ophthalmology Physician	$728.9K	$0
Rebecca Shields	NY	Ophthalmology Physician	$319.3K	$331.6K
Neal Adams	MD	Ophthalmology Physician	$497.9K	$5.3K
Susel Oropesa	CT	Ophthalmology Physician	$405.3K	$0

Nearby Providers

Other providers in the same ZIP code as Erol Verter, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The Center For Advanced Pediatrics, P.C	CT	Pediatrics Physician	$0	$7M
Mid-fairfield Child Guidance Center	CT	Community/Behavioral Health Agency	$0	$5.5M
Simon Bangiyev Dds, Md, PC Dba Premier Oral Surgery	CT	Oral and Maxillofacial Surgery (Dentist)	$0	$5.3M
Keystone House Inc.	CT	Mental Illness Community Based Residential Treatment Facility	$0	$3.4M
Allergy Center Of Connecticut, PC	CT	Allergy & Immunology Physician	$0	$2.6M
Richard A. Fichman, Md PC	CT	Ophthalmology Physician	$0	$2.5M
Myeyedr Optometry Of Connecticut, LLC	CT	Optometrist	$0	$2.3M
East Avenue Pediatrics PC	CT	Pediatrics Physician	$0	$1.8M
Robert L. Weiss, Md, PC	CT	Specialist	$0	$1.8M
Norwalk Family Dental, PC	CT	Dental Clinic/Center	$0	$1.3M

Erol Verter — Billing Profile & Reimbursement Data

Sign up for Erol Verter — Billing Profile & Reimbursement Data policy alerts

Erol Verter — Billing Profile & Reimbursement Data

Sign up for Erol Verter — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References